HBOT for Erectile Dysfunction | NorCal Hyperbarics Concord, CA

Erectile dysfunction (ED) is defined as the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. It affects an estimated 30 million men in the United States, with prevalence increasing markedly with age — affecting approximately 40% of men at age 40 and 70% of men at age 70. ED is not an inevitable part of aging, however: it is a medical condition with identifiable causes and effective treatments.

The majority of ED in men over 40 is vasculogenic — caused by the same atherosclerotic and endothelial dysfunction that drives coronary artery disease and peripheral vascular disease. ED is now recognized as an early biomarker of systemic cardiovascular disease: because the cavernous arteries (diameter approximately 1 to 2 mm) are smaller than coronary arteries (3 to 4 mm), they manifest the effects of atherosclerosis and endothelial dysfunction earlier. Men who develop ED are at significantly elevated risk for cardiac events within the following 5 to 10 years, making ED both a quality-of-life concern and a cardiovascular warning signal that warrants comprehensive evaluation.

Other causes of ED include diabetic cavernosal nerve damage, post-prostatectomy cavernous nerve injury, Peyronie's disease (penile fibrosis), hormonal deficiency (testosterone, thyroid), venous leak, and psychogenic factors. NorCal Hyperbarics' integrated approach — combining HBOT for vascular rehabilitation with BHRT for hormonal optimization — addresses multiple contributing factors simultaneously, making it a uniquely comprehensive ED treatment option in the Contra Costa County and Bay Area region.

Approximately 80% of erectile dysfunction cases have an organic (physiological) rather than purely psychological cause, and the majority of organic ED cases involve vascular pathology: insufficient arterial inflow through the cavernous arteries caused by atherosclerotic plaque, endothelial dysfunction, or fibrosis in the corpora cavernosa. The mechanism of erection requires robust endothelial nitric oxide synthase (eNOS) activity in cavernous artery endothelium to produce the nitric oxide (NO) that drives smooth muscle relaxation, penile engorgement, and rigidity. When endothelial function is compromised by atherosclerosis, diabetes, hypertension, or radiation damage, this NO-mediated pathway fails.

HBOT restores this pathway at the cellular level through two primary mechanisms. First, it stimulates angiogenesis in the corpora cavernosa through VEGF upregulation and endothelial progenitor cell mobilization — growing new capillaries that restore the vascular density needed for adequate penile oxygenation. Second, it directly restores eNOS activity in cavernous artery endothelial cells through the shear stress-dependent NO pathway, rebuilding the biological capacity for NO-mediated vasodilation that PDE5 inhibitors can only partially compensate for pharmacologically. This distinction is critical: sildenafil and tadalafil amplify residual NO signaling but cannot restore function when endothelial NO production has been sufficiently depleted.

Randomized controlled trials from Israeli research groups led by Dr. Ilan Gruenwald and colleagues, published in the Journal of Sexual Medicine, have demonstrated significant improvements in IIEF (International Index of Erectile Function) scores, erection hardness, and penetration ability in vasculogenic ED patients treated with HBOT — with 80% of patients achieving meaningful improvement in some series. For post-prostatectomy patients, HBOT is being increasingly incorporated into penile rehabilitation protocols to maintain cavernosal oxygenation and support cavernous nerve recovery during the post-surgical period. At NorCal Hyperbarics, HBOT for ED is often integrated with the clinic's BHRT (testosterone therapy) and other optimization services for a comprehensive men's health approach.